Products
Platform
Research
Market
Learn
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.08 | - |
NAV | ₹17.32 | - |
Fund Started | 14 Sep 2023 | - |
Fund Size | ₹1896.11 Cr | - |
Exit Load | Exit load of 1%, if redeemed within 30 days. | - |
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹100
-
Expense Ratio
2.08
-
NAV
₹17.32
-
Fund Started
14 Sep 2023
-
Fund Size
₹1896.11 Cr
-
Exit Load
Exit load of 1%, if redeemed within 30 days.
-
Returns
1 Year | 4.70% | - |
3 Year | - | - |
5 Year | - | - |
1 Year
4.70%
-
3 Year
-
-
5 Year
-
-
Holding Analysis
Equity | 99.01% | - |
Cash | 0.99% | - |
Equity
99.01%
-
Cash
0.99%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.47% |
Divi's Laboratories Ltd. | 7.76% |
Glenmark Pharmaceuticals Ltd. | 6.93% |
Lupin Ltd. | 6.84% |
Alkem Laboratories Ltd. | 5.94% |
Max Healthcare Institute Ltd. | 4.66% |
Ipca Laboratories Ltd. | 4.50% |
Cipla Ltd. | 4.32% |
Torrent Pharmaceuticals Ltd. | 3.81% |
Krishna Institute of Medical Sciences Ltd | 3.64% |
-
Fund Manager
Name | Dhruv Muchhal | - |
Start Date | 10 Sep 2025 | - |
Name
Dhruv Muchhal
-
Start Date
10 Sep 2025
-
About Fund
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | - |
Launch Date | 14 Sep 2023 | - |
Description
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
-
Launch Date
14 Sep 2023
-